FDA Approves Wainua: AstraZeneca's Eplontersen for hATTR-PN

The U.S. Food and Drug Administration (FDA) has granted eplontersen (Wainua) approval, marking a significant advancement in the treatment of hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN). This FDA eplontersen approval provides a new therapeutic option for patients affected by this rare, progressive, and fatal disease. Developed by AstraZeneca, Wainua addresses the underlying cause of hATTR-PN by reducing the production of transthyretin (TTR) protein.

Drug Overview

Eplontersen (Wainua) is an antisense oligonucleotide designed to reduce the hepatic production of transthyretin (TTR) protein. It is indicated for the treatment of Hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN), a rare, progressive, and fatal disease caused by mutations in the TTR gene leading to amyloid fibril deposition. The drug works by selectively binding to TTR mRNA, promoting its degradation and thereby reducing the amount of TTR protein produced in the liver.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for hereditary transthyretin-mediated amyloid polyneuropathy, with eplontersen most exposed to upcoming decisions. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Clinical Insights

Eplontersen (Wainua) has been evaluated in a Phase III clinical trial. The primary endpoint was the Neuropathy Impairment Score (NIS). Clinical trials demonstrated improvement in neuropathy impairment scores and quality of life measures (Norfolk QOL-DN) over a period of 12-18 months. Observed adverse events included injection site reactions, thrombocytopenia, renal function changes, and potential liver enzyme elevations.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Regulatory Context

Drugs for rare diseases like hATTR-PN often follow expedited FDA pathways such as Orphan Drug Designation, Fast Track, and Priority Review to accelerate approval based on surrogate or clinical endpoints demonstrating meaningful benefit. Class-typical adverse events for antisense oligonucleotides include injection site reactions, thrombocytopenia, renal function changes, and potential liver enzyme elevations. Monitoring protocols are standard in clinical use.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for hereditary transthyretin-mediated amyloid polyneuropathy pricing, access, and launch sequencing.

Market Impact

The approval of eplontersen (Wainua) enters a market where existing treatments for hATTR-PN include tafamidis, patisiran, and inotersen. With an estimated 5,000-10,000 patients in the US, the drug may provide a differentiated treatment option with potentially more convenient subcutaneous dosing and competitive safety profile versus existing TTR stabilizers and RNA interference therapies. Eplontersen's antisense oligonucleotide mechanism and subcutaneous administration may offer improvements in dosing convenience and safety compared to tafamidis, patisiran, and inotersen.

IntelligenceStrategic Takeaways▾

AstraZeneca's Wainua, also known as Eplontersen, has received FDA approval for the treatment of hATTR-PN, marking a significant advancement in patient care.

Future Outlook

Future developments for eplontersen (Wainua) may include exploring label expansions and combination trials to further enhance its therapeutic potential in treating hATTR-PN. Further studies may also focus on long-term safety and efficacy data to solidify its position in the treatment landscape.

Frequently Asked Questions

References

References

1. U.S. Food and Drug Administration. FDA approval. Accessed 2026-04-05.

IntelligenceEvidence Quality▾

Claims are grounded in the cited primary and secondary sources, with editorial review applied before publication.

Related profiles

• eplontersen

Related coverage

• FDA Approves Lumasiran for PH1: What BD and Investors Should Know
• GSK’s Blenrep returns to the US market after FDA approves resubmission
• FDA approves Vertex’s Journavx as first non-opioid pain drug for acute pain